Online inquiry

IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3773MR)

This product GTTS-WQ3773MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets CEACAM6 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002483.7
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4680
UniProt ID P40199
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ3773MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2107MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ6292MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CS-1001
GTTS-WQ4375MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ8798MR IVTScrip™ mRNA-Anti-PDCD1, IBI-308(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-308
GTTS-WQ4299MR IVTScrip™ mRNA-Anti-SNCA, BIIB-054(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BIIB-054
GTTS-WQ10199MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7, LDP-02(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LDP-02
GTTS-WQ13135MR IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PF-04360365
GTTS-WQ3188MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARENEGYR
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW